Parallax Receives Approval on its Registration Into U.S. Government's System for Award Management, (SAM)
March 16 2020 - 6:20AM
InvestorsHub NewsWire
Parallax Receives Approval on its
Registration Into U.S. Government's System for Award Management,
(SAM)
Patented and FDA Approved Diagnostics
Platform Subject of Application for Contract Grant with U.S. Center
for Disease Control, (CDC)
NEW YORK, NY -- March 16, 2020 -- InvestorsHub NewsWire
-- Parallax Health Sciences,
Inc. (PRLX)
(''Parallax'' or the ''Company''), an outcome-driven connected
healthcare company, today announced it has received preliminary
approval for registration into the U.S. Government’s System for
Award Management, (“SAM”) as part of the Company’s efforts to work
with the Center for Disease Control and Prevention, (“CDC”) in
Atlanta, Georgia to obtain a contract grant with their Small
Business Group for the Company’s Immunoassay diagnostics analyzer
to detect the Coronavirus, (“COVID-19”).
As previously announced, these efforts coincide with the
Company’s strategic initiative for the creation of a rapid
screening test on its VT-1000 diagnostics device for COVID-19 that
when soon available will produce results within 15
minutes. The Company has already received 26-Federal Drug
Administration, (“FDA”) 510(K) approvals for biomarkers used in
conjunction with the VT-1000 desktop unit. The FDA approved 510(K)
tests include the following:
- Rotacube (Rotavirus)
- Rubella-Cube TM
- Cmv-Cube TM
- Target Quantitative, Hcg
- Target Strep A (Streptococcus Spp.)
- V-Trend Im Test (infect mononucleosis)
- Target Reader
- Target Cardiac, Ck-Mb
- Target Troponin 1
- Target C-Reactive
Protein Test – 1
- Target C-Reactive
Protein Test – 3
- Target Myoglobin
- Target Aso Test
- Pregnancy, HcG
- Target Hcg
- Target Quantitative Hog One Step
- V-Trend Target Rf Test
- Blue Dot Test
Pregnancy
- Target Cocaine Metabolites-R Test
- Target Cocaine Metabolites-V Test
- Target Cannabinoids-R Test
- Target Cannabinoids-V Test
- Target Amphetamines/ Methamphetamines-R Test
- Target Amphetamines/ Methamphetamines-V Test
- Target Opiate-R Test
- Target Opiate-V Test
The Company’s integrated remote patient monitoring and
diagnostic platform can be useful to assess and comfort patients in
alternative settings such as their home, and also for determining
which patients need to be seen in the hospital or if urgent care is
appropriate. The Company’s Good Health Outcomes™ platform can
enable healthcare providers to treat isolated patients and help to
prevent the spread of what is becoming an extremely contagious
virus.
Last week, the Bill & Melinda Gates Foundation said, “It is
partnering with Wellcome and Mastercard to commit $125 million in
seed funding toward an accelerator created to speed up development
of treatments for COVID-19.”
Last Friday at a press conference in Washington, DC, President
Trump committed additional funding to bring the total now to more
than $50 billion available for the development and testing of
COVID-19. Mr. Trump cautioned that many of the current
Covid-19 tests are not point-of-care, (“POC”) tests and they
typically take 24 hours or more to generate results.
President Trump, Vice President Pence, and officials from the
coronavirus task force held a briefing Sunday on the country’s
response to the COVID-19 pandemic. Vice President Pence commented,
“That testing will be expanded and that cost will never be a
barrier to any American who needs a test in getting the coronavirus
testing they require.”
“We are committed to working with those parties in the federal,
state and local governments as well as the laboratories and
universities in the private sector to making our diagnostic
analyzer and testing kits available in the healthcare community as
quickly as possible,” stated Paul Arena, Chief Executive Officer of
Parallax Health Sciences, Inc.
Also last Friday, Fox News with Bret Baier aired a Special
Report on COVID-19. The Company’s own Nathaniel Bradley,
Chief Technology Officer and President of Parallax Health
Management, was interviewed for the show. The footage can be
seen on our website at www.parallaxcare.com on
the landing page.
About Parallax Diagnostics
Parallax Diagnostics is a bio-medical company and wholly-owned
subsidiary of Parallax Health Sciences, Inc. Parallax Diagnostics
owns a line of 26 FDA approved, Point of Care diagnostic tests on a
single platform in the area of infectious disease, cardiac, medical
conditions, drugs of abuse, and pregnancy. Parallax
Diagnostics is developing a novel, handheld diagnostic testing
system that is simple, rapid and elegant, offering the potential to
transform the diagnostic landscape by transitioning critical tests
from the centralized lab directly to the hands of the physician or
clinicians. Our focus is on tests that detect and/or monitor
infectious diseases.
About Parallax Health Sciences
Parallax Health Sciences is a leading-edge technology,
outcome-driven telehealth company that allows for cost-effective
remote diagnosis, treatment, and monitoring of patients through
proprietary platforms of integrated products and services. The
Company's interoperable novel applications provide patients
point-of-care testing and monitoring with information communicated
via internet-based mobile phone applications that are agnostic as
to operating system and are built on highly sophisticated data
analytics. Information is retrieved in real-time by physicians who
are monitoring patients with chronic diseases or through biometric
feedback for health-related behavior modification, and is automated
for integration into electronic health records. The Company's
products and offerings capitalize on the digital transformation in
healthcare for improved patient compliance, diagnosis and
treatment, and support healthcare system cost savings and
efficiencies. For more information, please
visit www.parallaxhealthsciences.com or www.parallaxcare.com.
Investor Contact:
Paul Arena, CEO
paul@parallaxcare.com
cell 404-915-8449
Parallax Health Sciences (CE) (USOTC:PRLX)
Historical Stock Chart
From Apr 2024 to May 2024
Parallax Health Sciences (CE) (USOTC:PRLX)
Historical Stock Chart
From May 2023 to May 2024